Analysts expect Johnson & Johnson (NYSE:JNJ) to announce $1.79 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $1.75 and the highest estimate coming in at $1.84. Johnson & Johnson posted earnings of $1.68 per share during the same quarter last year, which would suggest a positive year over year growth rate of 6.5%. The business is expected to issue its next earnings report before the market opens on Tuesday, October 17th.

On average, analysts expect that Johnson & Johnson will report full year earnings of $7.18 per share for the current fiscal year, with EPS estimates ranging from $7.11 to $7.22. For the next fiscal year, analysts anticipate that the business will post earnings of $7.71 per share, with EPS estimates ranging from $7.50 to $7.90. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the previous year, the firm earned $1.74 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year.

Several equities research analysts recently issued reports on the company. BidaskClub cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 1st. Royal Bank Of Canada restated a “buy” rating and issued a $128.00 target price on shares of Johnson & Johnson in a report on Thursday, June 15th. UBS AG reiterated a “buy” rating and set a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Zacks Investment Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $148.00 price target on the stock in a research report on Thursday, July 27th. Finally, Credit Suisse Group reissued a “buy” rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Six investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have given a buy rating to the stock. Johnson & Johnson currently has an average rating of “Hold” and an average target price of $135.52.

Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.67% during midday trading on Friday, reaching $132.10. 3,888,431 shares of the company’s stock were exchanged. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The company’s 50-day moving average is $132.31 and its 200-day moving average is $129.75. The stock has a market cap of $354.56 billion, a P/E ratio of 22.35 and a beta of 0.78.

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a $0.84 dividend. This represents a $3.36 annualized dividend and a yield of 2.54%. The ex-dividend date of this dividend was Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the transaction, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the transaction, the vice president now directly owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by corporate insiders.

Several hedge funds have recently made changes to their positions in the stock. State Street Corp boosted its position in Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after buying an additional 6,656,371 shares during the period. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after acquiring an additional 4,332,612 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 717.9% in the second quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after acquiring an additional 3,289,763 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares in the last quarter. Hedge funds and other institutional investors own 65.90% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/1-79-eps-expected-for-johnson-johnson-jnj-this-quarter/1605989.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.